Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunnybrook Health Sciences Centre
With
University Health Network, Toronto
Unity Health Toronto
Scarborough General Hospital
Providence Healthcare
MODERNA : Nucleocapsid Modified messenger RNA BioNTech: Bio-Pharma new Technology
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with Chronic Kidney Disease (CKD)stage 3b-5 defined as an eGFR( estimated glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible. Stage 5 CKD will include patients receiving in-center hemodialysis, home dialysis (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the COVID-19 vaccine will be eligible for a third dose to be given 2-12 months following the second dose.
Age ≥18 at the time of study enrolment
You may not be if
Patients not vaccinated against COVID-19 vaccination.
Patients who received heterologous first two doses of vaccine
Patients with a severe allergic reaction to prior COVID-19 vaccination or any of the ingredients.
